Search

Your search keyword '"Sato Naoto"' showing total 4 results
Start Over Author "Sato Naoto" Journal international journal of oncology
4 results on '"Sato Naoto"'

3. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy

Author

WANG, DONGDONG, primary, SAGA, YASUSHI, additional, MIZUKAMI, HIROAKI, additional, SATO, NAOTO, additional, NONAKA, HIROAKI, additional, FUJIWARA, HIROYUKI, additional, TAKEI, YUJI, additional, MACHIDA, SHIZUO, additional, TAKIKAWA, OSAMU, additional, OZAWA, KEIYA, additional, and SUZUKI, MITSUAKI, additional

Published
2011
Full Text
View/download PDF

4. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy.

Author

Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujiwara H, Takei Y, Machida S, Takikawa O, Ozawa K, and Suzuki M

Subjects
Animals, Cell Line, Tumor, Disease Progression, Down-Regulation, Female, Humans, Immunohistochemistry, Indoleamine-Pyrrole 2,3,-Dioxygenase biosynthesis, Indoleamine-Pyrrole 2,3,-Dioxygenase genetics, Killer Cells, Natural pathology, Mice, Mice, Inbred BALB C, Mice, Nude, Ovarian Neoplasms genetics, Ovarian Neoplasms immunology, Transfection, Xenograft Model Antitumor Assays, Indoleamine-Pyrrole 2,3,-Dioxygenase immunology, Killer Cells, Natural enzymology, Ovarian Neoplasms enzymology, Ovarian Neoplasms therapy, RNA, Small Interfering administration & dosage, RNA, Small Interfering genetics
Abstract

This study examined the role of the immuno-suppressive enzyme indoleamine-2,3-dioxygenase (IDO) in ovarian cancer progression, and the possible application of this enzyme as a target for ovarian cancer therapy. We transfected a short hairpin RNA vector targeting IDO into the human ovarian cancer cell line SKOV-3, that constitutively expresses IDO and established an IDO downregulated cell line (SKOV-3/shIDO) to determine whether inhibition of IDO mediates the progression of ovarian cancer. IDO downregulation suppressed tumor growth and peritoneal dissemination in vivo, without influencing cancer cell growth. Moreover, IDO downregulation enhanced the sensitivity of cancer cells to natural killer (NK) cells in vitro, and promoted NK cell accumulation in the tumor stroma in vivo. These findings indicate that downregulation of IDO controls ovarian cancer progression by activating NK cells, suggesting IDO targeting as a potential therapy for ovarian cancer.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results